MedPath

CyPep-1

Generic Name
CyPep-1

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 23, 2025

CyPep-1 / CY-101: A Novel Dual-Mechanism Oncolytic Peptide in Clinical Development

I. Executive Summary

The investigational agent CyPep-1, now predominantly referred to as CY-101 in its oncological development by Cytovation AS, represents a novel, first-in-class therapeutic candidate. It is a synthetic, 27 D-amino acid cationic lytic peptide engineered for the treatment of various cancers.[1] A significant attribute of CY-101 is its innovative dual mechanism of action. The peptide directly targets and disrupts cancer cell membranes, leading to rapid cell lysis and the release of tumor antigens, a process designed to induce immunogenic cell death and an in situ vaccination effect.[3] Concurrently, CY-101 has been shown to inhibit the Wnt/β-catenin signaling pathway, a critical oncogenic driver in many malignancies.[2] This dual approach distinguishes CY-101 from many other oncolytic agents. The evolution in nomenclature from the general research term "CyPep-1" to the oncology-specific "CY-101" signifies a deliberate strategic focusing of its development program, reflecting an increasing understanding of its specific mechanisms in cancer and a commitment to this therapeutic area. This is further differentiated from an earlier formulation, CyPep-H1, which was explored for dermatological conditions.[7] Such shifts in designation often occur as a product matures and its lead indication becomes more clearly defined, underscoring Cytovation's strategic direction for CY-101 in oncology.

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.